# Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

> **NCT00422877** · PHASE2 · TERMINATED · sponsor: **American Regent, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Cancer of the Liver

## Interventions

- **DRUG:** Taxoprexin

## Key facts

- **NCT ID:** NCT00422877
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor suspended development of the drug on September 3, 2008.
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422877, "Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00422877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*